Business, energy, technology, markets and global industry news from Business News Today

PATHFINDER 2

PharmaDeviceNews PATHFINDER 2
GRAIL's Galleri multi-cancer blood test faces a pivotal FDA advisory committee review as GRAL shares surge on renewed expectations for the cancer-screening technology. Representative image.
Medical Devices & Diagnostics

Why GRAIL stock exploded after FDA documents on Galleri cancer blood test

GRAIL shares recorded their strongest session in more than a year after FDA reviewers raised no major analytical or primary safety concerns ahead of a September 23 advisory committee vote on Galleri, the blood test designed to screen adults for signals from more than 50 cancers.

Read More
A laboratory blood sample illustrates GRAIL’s Galleri multi-cancer early detection test ahead of an FDA advisory panel review following mixed NHS-Galleri trial results. Representative image.
Medical Devices & Diagnostics

FDA panel to review GRAIL Galleri cancer blood test after pivotal NHS trial misses primary endpoint

GRAIL, Inc. will face a potentially defining regulatory examination on September 23, 2026, when outside advisers to the United States Food and Drug Administration review the premarket approval application for its Galleri multi-cancer early detection blood test. The FDA’s Molecular and Clinical Genetics Panel is scheduled to discuss and vote on whether the available evidence

Read More